22:13:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-06-28 Årsstämma 2024
2024-06-12 X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 Kvartalsrapport 2024-Q1
2024-02-27 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-07-03 Extra Bolagsstämma 2023
2023-06-13 Årsstämma 2023
2023-05-24 X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-26 X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-05-23 X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt övrig grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Bolaget grundades 2008 och har huvudkontoret i Uppsala.
2024-02-15 14:30:00

Q-linea today announces that clinical insights from two prospective studies will be presented at the AMCLI congress. Data will be shared both from the largest comparative study performed in Europe so far between rapid AST systems and from the ongoing health economics research (HEOR) study Lifetimes.

At the upcoming conference, AMCLI (Associazione Microbiologi Clinici Italiani) National Congress in Rimini, Italy on March 9, 2024, Q-linea will host a workshop titled “ASTar in action: Rapid MIC in the management of the patients with bloodstream infection”. The workshop will showcase clinical insights from two prospective studies.

  • Prof. Alexia Verroken, from Cliniques Universitaires Saint-Luc, Brussels, will present the results of a trial investigating the clinical impact of rapid AST on positive blood cultures from 200 patients with bacteremia. The study is a comparative analysis of Q-linea’s ASTar system with two other rapid AST technologies, providing insights into user-friendliness, performance, and clinical impact of each approach.
  • Prof. Maurizio Sanguinetti, from Universitá Cattolica del Sacro Cuore, Rome, will present interim data from the ongoing Lifetimes health economics study, including 160 prospective ICU patients with bloodstream infections.

“It is an honor to present ASTar for the first time at this national conference, alongside these distinguished speakers. The workshop will offer a unique opportunity to showcase ASTar’s clinical impact in real-life scenarios,” said Dr. Tiziana Di Martino, Chief Medical Officer of Q-linea.

"I look forward to see the results from the largest comparative study between rapid AST systems performed in Europe so far. I am honored that the study’s principal investigator Prof. Alexia Verroken has chosen to participate in Q-linea’s workshop at the conference to present the results. If the results are in line with the performance ASTar has shown in several previous independent studies, I am confident that it will be positive for ASTar and Q-linea. I also look forward to Prof. Maurizio Sanguinetti presenting the first set of data from the HEOR study currently ongoing in Italy. The complete study results are planned to be presented later during the year", said Jonas Jarvius, President and CEO of Q-linea.